Background. Herpes simplex virus (HSV) suppressive therapy reduces genital and plasma human immunodeficiency virus type 1 (HIV-1) RNA over periods up to 3 months, but the long-term effect is unknown.
. Two trials of acyclovir administered at a dosage of 400 mg bid have shown less effect, one finding no reduction in cervico-vaginal HIV-1 RNA detection [18] and another finding a reduction in frequency of cervico-vaginal HIV-1 RNA detection and plasma HIV-1 RNA load but no effect on genital HIV-1 load among those shedding [19] .
Here, we report the results of a placebo-controlled RCT of the effect of acyclovir administered at a dosage of 400 mg bid on genital and plasma HIV-1 RNA over a 24-month period.
METHODS
Study participants. Women 16-35 years of age who worked in recreational facilities or were self-employed as food handlers in 19 communities in northwest Tanzania were invited to attend a mobile study clinic for HSV-2 and HIV-1 antibody screening, as previously described [20] . Women returned 8-12 weeks later for their HSV-2 results and were eligible for enrollment if they were HSV-2 seropositive, lived in a study community and would not be travelling at the time of the next visit, were not pregnant or breastfeeding, and were not planning pregnancy or planning to move outside of the study communities within the next 2 years. Women were not enrolled if they did not understand the key trial concepts, had a history of epilepsy, or were too ill to participate. Trial details have been published elsewhere [21] . Women were enrolled regardless of HIV status, and knowledge of HIV status was not required. In total, 1305 women (821 HIV-seronegative and 484 HIV-seropositive women) were randomized in 3 phases (January-April 2004, July-September 2004, and January-May 2006) and were followed up for up to 30 months. There was no effect of acyclovir administered at a dosage of 400 mg bid on HIV acquisition (rate ratio, 1.08; 95% confidence interval [CI] , 0.64-1.83) [21] . In this article, we report the effects on genital and plasma HIV-1 RNA among the HIV-positive participants.
Trial procedures. After informed consent was obtained, women were enrolled into the trial, and biological samplesincluding blood samples, urine specimens, genital swab samples, and a cervico-vaginal lavage (CVL) sample [22] -were obtained. Genital ulcers were swabbed. Participants were randomized to receive oral acyclovir (400 mg bid) or matching placebo [21] . Participants attended the study clinic every 3 months and were given a further supply of study tablets. Participants were asked to avoid vaginal cleansing before attending visits and were tested for pregnancy if it was suspected. Pregnant women were withdrawn from study tablets. Participants who chose to withdraw or who were withdrawn from tablets remained in the trial for follow-up if possible. At each visit, symptoms of reproductive tract infections (RTIs) were treated syndromically according to Tanzanian national guidelines. Women with laboratory-confirmed RTIs (with the exception of asymptomatic bacterial vaginosis) were offered treatment. Genital ulcers were swabbed. Women were offered family planning, condoms, and risk reduction counselling, as well as voluntary counselling and testing for HIV. Every 6 months, a blood sample was obtained for determination of plasma viral load and, with the exception of the visit at 18 months, genital samples and a CVL sample were collected. After results from a trial of short-duration HSV suppressive therapy that reported a reduction in the frequency and quantity of genital HIV-1 RNA and a reduction in plasma HIV-1 RNA load [15] , additional blood samples were obtained for CD4 cell counts at 30 months for phase I participants, at 24 and 30 months for phase 2 participants, and at 6 and 12 months for phase 3 participants.
Adherence was estimated by tablet count at each visit. Women were given specific additional counselling and advice if adherence problems were identified (through comparison of tablet counts and elapsed days) or if tablets were reported missed, damaged, or lost. Adherence was estimated for the preceding 3-month period and defined as unknown if a participant had not attended the previous visit, forgot to bring tablets to the clinic, or brought back too few tablets and reported them as lost, stolen, or damaged. Approximately 1 month after each scheduled visit, a mobile adherence-support team visited participants. A random sample of 161 urine specimens (80 and 81 from the acyclovir and placebo arms, respectively), either collected by the adherence team between the 6-month and 9-month scheduled visits or from the 6-month, 12-month, and 24-month scheduled visits were tested using high-performance liquid chromatography [23] for acyclovir by an independent laboratory. An independent data monitoring committee periodically reviewed trial data, including serious adverse events [24] , which were collected at each visit.
Free antiretroviral therapy became available in regional and district hospitals in the study area during the trial. HIV-positive women who knew their HIV status were referred to HIV care and treatment centers for assessment and were offered transport if requested. At the end of the trial, travel costs were provided to enable them to attend their center for the next 12-18 months. HIV-positive pregnant women were provided with transport to reach the nearest center offering prevention of mother-to-child HIV transmission services.
Laboratory analyses. Screening serum samples were tested for HSV-2 antibodies, and screening and randomization serum samples were tested for HIV-1 antibodies [20] . Randomization serum samples were tested for syphilis, and vaginal and cervical swab samples were tested for other RTIs as described elsewhere [25, 26] . CD4 T lymphocytes were quantified in blood samples (Coulter Manual CD4 Kit; Beckman Coulter). Genital ulcer swab samples were tested for Treponema pallidum, HSV, and Haemophilus ducreyi by polymerase chain reaction (PCR) [27] [28] [29] [30] [31] .
CVLs were centrifuged (3500 rpm for 10 min), separated, and stored at Ϫ20ЊC for 2-3 weeks and then at Ϫ80ЊC before transport with plasma samples to Inserm U743 (Paris, France). Fiftythree women were ineligible for pregnancy-related reasons (positive pregnancy test result, reported pregnancy, or planned pregnancy); 2 women were breastfeeding; 17 women were planning to move or travelling at the next follow-up appointment; 9 women were too ill to participate; and 2 women did not understand the key concepts of the trial. 2 Attendance calculated as percentage of those eligible for mITT (ie, not censored because of pregnancy or known to have died). Discrepancies between the number of patients eligible and attended and the number of patients analyzed are the result of cervico-vaginal lavage samples that were not obtained or analyzed. 3 Analyzed for primary outcome (cervico-vaginal human immunodeficiency virus type 1 [HIV-1] RNA) for primary mITT analysis. HSV-2, herpes simplex virus type 2; LTFU, lost to follow-up.
CVL supernatants were visually examined for blood. Nucleic acids were extracted from CVL supernatants and plasma (NucliSens miniMAG and later easyMAG extraction system; bioMérieux) and CVL cell pellets (QIAamp DNA Blood Mini Kit. Qiagen).
Genital and plasma HIV-1 RNA was quantified by in-house real-time PCR with a forward primer that was 3 nucleic acids shorter than previously reported [32] to facilitate detection of more HIV-1 subtypes. HSV DNA was quantified in CVL supernatants by in-house real-time PCR [33] . HSV DNA-positive samples from randomization were typed [34] , and all strains were HSV-2. Y-chromosome DNA (Quantifiler Y Human Male DNA Quantification kit; Applied Biosystems) was tested for using nucleic acids from the CVL cell pellet. Quantifications were performed using Applied Biosystems 7300 Real-time PCR System (Applied Biosystems). The laboratory registered with an external blinded quality-control program for HIV-1 RNA (Quality Control for Molecular Diagnostics; Glasgow, UK). A commercial unblinded standard was used to confirm the HSV DNA assay (HSV-1/HSV-2 Clear QC Panel; Argene). Statistical methods. The primary objective was to determine the effect of HSV suppressive therapy on the detection and quantity of cervico-vaginal HIV-1 RNA at 6 months. The original sample size of 1000 HSV-2-seropositive women was powered to determine effects on HIV acquisition among HIVnegative participants [21] . HIV prevalence was estimated at 40% [35] . Assuming 400 HIV-positive participants and 15% loss to follow-up or censored for pregnancy at 6 months, we had 195% power to detect a reduction in detectable genital HIV-1 RNA at 6 months from 50% in the placebo arm [5, 36] to 30% in the acyclovir arm and a 0.5-log reduction in HIV-1 RNA load in women shedding HIV-1 RNA, assuming a standard deviation of 0.8 log [4] .
The primary analysis was a modified intention-to-treat analysis in which women were censored at the earliest of loss to follow-up, death, positive pregnancy test result, or end of follow-up. Primary outcomes were detection and quantity of cervico-vaginal HIV-1 RNA. Secondary outcomes were detection and quantity of cervico-vaginal HSV DNA, plasma HIV-1 RNA load, GUD presence on examination, and CD4 cell count. Genital viral load outcomes were compared only among women with detectable viral shedding. The primary analysis time-point was 6 months. Secondary analysis time-points were 12 months and 24 months.
Logistic and linear regression models were used to analyze binary and continuous outcomes, respectively. For binary outcomes, the primary measure of effect was an unadjusted odds ratio (OR). For viral load outcomes, the primary measure of effect was mean difference of log viral load between arms, adjusted for baseline plasma HIV-1 RNA or baseline HSV DNA detection, as appropriate. Adjustment was made for baseline plasma HIV-1 RNA load, because this provides a more stable measure than does cervico-vaginal HIV-1 RNA load.
Data from the 3 follow-up visits (at 6, 12, and 24 months) were combined to increase power, assuming a constant effect over time, and analyzed using general estimating equations Adjusted measure of effect excludes 1 woman in the acyclovir arm who had no baseline plasma viral load measurement. (GEE) regression models to allow for within-woman correlation. The log CD4 cell count was analyzed combining data from different visits using GEE linear regression. Participants were censored at antiretroviral therapy initiation for plasma HIV-1 RNA and CD4 cell count outcomes only. The secondary analyses were intention-to-treat analysis (including pregnant women attending follow-up visits) and an analysis stratified by adherence. An a priori restricted analysis that excluded samples with visible blood was performed for the primary outcomes. Prespecified subgroup analyses were performed using interaction tests to determine whether the effect of acyclovir on cervicovaginal HIV-1 RNA levels differed according to baseline cervico-vaginal HIV-1 RNA detection, baseline detection of both cervico-vaginal HIV-1 RNA and HSV DNA, plasma HIV-1 RNA levels, Y-chromosome detection at follow-up, and sexually transmitted infection presence at follow-up.
Quantitation thresholds were 360 copies/mL for cervico-vaginal HIV-1 RNA and 300 copies/mL for cervico-vaginal HSV DNA and plasma HIV-1 RNA. For cervico-vaginal shedding, viral loads below the threshold were classed as undetectable. Plasma HIV-1 RNA levels below the threshold were allocated one-half of the threshold value for analysis.
Data were double entered and verified in Dbase IV (dataBase Intelligence), and analyses were conducted using Stata software, version 10.0 (Stata).
Ethics. The protocol was approved by the Medical Research Coordinating Committee of Tanzania and the London School of Hygiene and Tropical Medicine Ethics Committee. The trial was registered with Current Controlled Trials (ISRCTN35385041).
RESULTS

Enrollment.
In total, 2719 women were screened for HSV-2 and HIV-1 antibodies. Of 751 women with dual seropositivity, 465 (61.9%) returned for the randomization visit, were eligible for enrollment, and consented to participate. In addition, 19 women who seroconverted to HIV-1 between screening and randomization were eligible. In total, 484 women were enrolled (253 randomized to acyclovir and 231 randomized to placebo; Figure 1 ).
Cohort characteristics at enrollment. The median age of the participants was 28 years (interquartile range, 25-32 years). Ninety women (18.6%) were married or living as married, and 223 (46.1%) worked as local food handlers (Table 1) . Approximately one-third (31.2%) of the participants reported a history of genital ulceration or blisters. RTIs were prevalent. Cervicovaginal HIV-1 RNA and HSV DNA were detected in 52.6% and 14.5% of CVLs, respectively. In total, 279 women (57.6%) accepted voluntary counselling and testing at enrollment, and a further 68 (14.0%) accepted voluntary counseling and testing during follow-up.
Follow-up. Follow-up for the primary outcome (cervicovaginal HIV-1 RNA) is shown in Figure 1 . Overall, 88%, 86%, and 79% of women eligible for the modified intention-to-treat analysis attended the 6-month, 12-month, and 24-month visits, respectively. Fifty-two women (10.7%) were censored for pregnancy before 24 months, 39 (8.1%) died, and 81 (16.9%) were lost to follow-up for other reasons, including 20 (4.1%) who requested trial withdrawal. For plasma HIV-1 RNA and CD4 cell count outcomes, 7 women were censored at antiretroviral therapy initiation before 6 months (4 in the acyclovir arm and 3 in the placebo arm), 3 between 6 months and 12 months (1 in the acyclovir arm and 2 in the placebo arm), and 14 between 12 months and 24 months (8 in the acyclovir arm and 6 in the placebo arm).
Effect of acyclovir on cervico-vaginal HIV-1 RNA. There was little evidence of an effect of acyclovir on detection or quantity of cervico-vaginal HIV-1 RNA (Table 2) . At 6 months, the prevalence of cervico-vaginal HIV-1 RNA detection was 41.3% and 44.0% in the acyclovir and placebo arms, respectively (OR, 0.90; 95% CI, 0.60-1.33). There was little difference in HIV-1 RNA quantity by arm (adjusted mean difference, Ϫ0.01 log 10 copies/mL; 95% CI, Ϫ0.20 to 0.19). Similar results were seen at 12 months and 24 months (Table 2 ) and in the secondary intention-to treat analysis (data not shown). Combining data from all 3 visits, there was a suggestion of an impact on HIV-1 RNA detection (OR, 0.82; 95% CI, 0.61-1.11), which was stronger among samples without visible blood (OR, 0.71; 95% CI, 0.51-0.97; Table 2 ), but there was little difference in quantity in this sub-group. There was no evidence that the impact of acyclovir differed between the categories of the prespecified subgroups. Effect of acyclovir on cervico-vaginal HSV DNA and GUD. At 6 months, HSV DNA was detected in 9.4% of women in the acyclovir arm and 11.5% of women in the placebo arm (OR, 0.80; 95% CI, 0.42-1.51; Table 3 ). Similar results were observed at 12 months and 24 months, over the whole followup period (Table 3) , and in the secondary intention-to-treat analysis (data not shown). There was little difference in HSV DNA quantity (Table 3) .
Although there were few clinically diagnosed GUD episodes during follow-up, there was a reduction in the number of GUD episodes that occurred in the acyclovir arm Adherence. Median estimated adherence, by tablet count, for the 3-month period preceding each analysis point was 91.9% (interquartile range, 64.0%-99.5%) ( Table 4) . Using this estimate, unknown adherence (in ∼20% women) was assumed to be low. Acyclovir was detected in 45 (56%) of the 80 tested urine specimens that were obtained from 69 women in the acyclovir arm.
Effect of acyclovir on cervico-vaginal HIV RNA and HSV DNA stratified by adherence. Among women with estimated adherence у90%, there was some evidence of an effect of acyclovir on HSV DNA detection (repeated measures analysis, 7.2% vs 11.6% of visits; OR, 0.60; 95% CI, 0.33-1.09; Table 3; for interaction) and, to a lesser extent, on HIV-1 RNA P p .045 detection (44% vs 52% of visits; OR, 0.74; 95% CI, 0.50-1.09; Table 2; for interaction). However, there was no evi-P p .40 dence for an effect on HSV DNA or HIV-1 RNA loads in women with estimated adherence у90%.
Effect of acyclovir on plasma HIV-1 RNA and CD4 cell count. Plasma HIV-1 RNA loads were similar in both arms (Table 5) . At 6 months, the adjusted mean difference was 0.04 log copies/mL (95% CI, Ϫ0.07 to 0.15). Results were similar at all visits, and there was no evidence for an effect in those with estimated adherence у90% (Table 5) .
Conversely, there was evidence of an effect of acyclovir on CD4 cell counts. Geometric mean CD4 cell counts were 346 cells/mL in the acyclovir arm and 271 cells/mL in the placebo arm (Table 5 ; mean difference, 0.11 log cells/mL; 95% CI, 0.03-0.19).
Serious adverse events. In total, 147 serious adverse events were documented in 52 women (20.6%) in the acyclovir and 59 women (25.5%) in the placebo arm. These were mainly malaria or HIV-related adverse events, and no serious adverse event was attributed to acyclovir use. There were 48 deaths (20 in the acyclovir arm and 28 in the placebo arm), 30 life-threatening illnesses (16 and 14, respectively) and 69 hospitalizations (33 and 36, respectively).
DISCUSSION
We assessed the effect of providing HSV suppressive therapy (acyclovir administered at 400 mg bid) for up to 24 months and found little impact on the prevalence or quantity of either genital HIV-1 RNA or HSV DNA or on plasma HIV-1 RNA. These results contrast with those of previous RCTs that assessed suppressive therapy regimes of valacyclovir (500 mg bid) or acyclovir (800 mg bid), which reported substantial reductions in genital (0.2-0.5 log 10 copies/mL) and plasma (0.3-0.5 log 10 copies/mL) HIV-1 RNA [13] [14] [15] [16] [17] over periods of up to 3 months. A similar reduction in plasma HIV-1 RNA was seen in 2 RCTs using acyclovir administered at a dosage of 400 mg bid (0.34 and 0.25 log 10 copies/mL) [19, 37] . The latter examined the effect of this regimen over 24 months. However, trials of acyclovir at a dosage of 400 mg bid [18, 19] have generally reported weaker effects on genital HIV-1 RNA and HSV DNA. This may be partially attributable to different regimens, but suboptimal adherence may also have been a factor in one trial [18] .
The difference between our results and previous trial findings is likely to be attributable mainly to a combination of suboptimal adherence and the regimen used. There was some evidence that, for HSV DNA and, to a lesser extent, HIV-1 RNA, the effect of acyclovir was better in those individuals with estimated adherence у90%. However, the absence of a convincing effect on HSV DNA overall and the weak effect in this subgroup may suggest that adherence was lower than estimated. Median estimated adherence, 190% at each visit, was estimated using tablet counts, which does not guarantee that tablets were actually taken. Results from the urine analysis in which only 56% of samples had detectable acyclovir would support this. The mobile clinics, quarterly clinic and adherence support visits, and more mobile trial population made achieving high adherence especially challenging in this trial, compared with other trials conducted among HIV-infected individuals [13] [14] [15] [16] [17] 19] . Alternatively, adherence estimates may be reasonably accurate, but participants may not have been adhering to the 12-h regimen. The short half-life of acyclovir (∼3 h) [38] means that effective HSV-2 suppression may require very high compliance with a twice-daily regimen, which may be difficult to sustain, especially for asymptomatic or mobile individuals. In contrast, valacyclovir, which is broken down into acyclovir following absorption, has an oral bioavailability of 3.5-5.5 times that of acyclovir [39] , and trough plasma acyclovir concentrations were approximately twice as high in individuals taking valacyclovir (500 mg bid) as they were in individuals taking acyclovir (400 mg bid) in a trial that compared the 2 regimens [40] . A trial that compared the effect of valacyclovir (1 g bid) and acyclovir (400 mg bid) on genital and plasma HIV is underway in the United States (ClinicalTrials.gov identifier no. NCT00527618).
Other factors that may help to explain the results include the stage of HSV-2 infection. Most (82%) of swabbed ulcers at baseline had no identified etiology: this percentage is higher than that reported in other studies [41] and may suggest some misidentification of ulcers by the clinicians at this time. In contrast, we observed few GUD episodes during follow-up, which may suggest that this cohort acquired HSV-2 infection several years before the trial, because the frequency of GUD recurrences decreases over time [42] . HSV shedding in the placebo arm was also less frequent than it was in other trials, although rates are difficult to compare because of different methods of sample collection and analysis. Other RTIs were also prevalent in this population, which may have diluted any HSV-2-associated effects on HIV. Finally, most participants practiced vaginal cleansing, and at 23% of visits, cleansing within the previous 3 h was reported. This may have affected cervico-vaginal HIV RNA and HSV DNA detection, but excluding these women does not affect results, and this does not explain the absence of effect on plasma HIV-1 RNA.
Errors in labelling or drug resistance are unlikely to explain our results, because quality control checks confirmed labelling and quality of the acyclovir tablets, and acyclovir resistance is rare, remaining !5% in HIV seropositive individuals [43] . Further work to examine acyclovir resistance in this cohort is underway.
Trial protocol differences may partly explain the difference in shedding results. Genital HIV-1 RNA loads show greater variability when collected by CVL than when collected by swab [44] . Of other RCTs using CVLs [14, 18, 19] , one found no effect of suppressive therapy on HIV-1 RNA detection [18] , and another [19] reported an effect on frequency of HIV-1 RNA detection but not on quantity, despite a reduction in plasma HIV-1 RNA. However, these trials also used acyclovir at a dosage of 400 mg bid, making it difficult to disentangle the effects of regimen from those of sampling method. Some trials did not examine menstruating women [15, 19] . By including these samples, our results may be underestimated. Our analysis that was restricted to samples without visible blood found a 25% reduction in HIV-1 RNA detection but no effect on quantity. However, there was no evidence for a substantial effect on HSV DNA, and although recent in vitro data suggest that acyclovir may directly inhibit HIV-1 reverse transcriptase [45, 46] , this is not suggested by our finding of an absence of an effect on plasma viral load.
We did, however, find some evidence for a difference in CD4 cell counts between treatment arms. One other trial examined the effect on CD4 cell count but found no effect [19] . Our result should be interpreted with caution because of the lack of impact on other endpoints and may be attributable to chance or to baseline imbalance, because there are no baseline CD4 cell counts.
A trial of acyclovir (400 mg bid) recently reported no effect on HIV transmission from HIV-positive to HIV-negative partners despite a 0.25-log reduction in plasma HIV-1 RNA and a 73% reduction in clinical HSV-2 reactivations [37] . Additional trials are needed to investigate the effect of HSV suppressive therapy on CD4 cell counts and whether this may be translated into any clinical benefit. Our results suggest that the regimen of acyclovir (400 mg bid) is unlikely to substantially reduce HIV transmission or plasma HIV-1 RNA levels in a highrisk mobile population, where it may be difficult to achieve the high levels of adherence that appear to be necessary for HSV-2 suppression.
